LAUSR

(47.8%) and polytrauma (18.6%). Patient comorbidities included history of deep vein thrombosis (27.2%), hypercoagulable condition (6.81%), and cancer (27.6%). The mean follow-up for the cohort was 35.7 months. Table I summarizes the complication rates of the removable and permanent PIVCFs, and Table II summarizes the complication rates by filter type. Asymptomatic tine penetration was the most common adverse event (127 [24.1%]). Fifteen (13 Cook Celect, 2 B-Braun VenaTech) patients (2.84%) had symptoms from tine penetration, which included gastrointestinal bleeding, pain, infection, or retroperitoneal hematoma. There were 22 (4.17%) filters (14 Cook Celect, 6 Gunther Tulip, 1 Cordis Trapease, 1 other) that embolized into the heart or lung and seven (1.33%) that caused caval thrombosis (2 Cook Celect, 4 Gunther Tulip, 1 Cordis Trapease). Conclusions: IVCFs are commonly used in contemporary practice. Common adverse events include tine penetration, embolization, and caval thrombosis but are more common in retrievable filters and seem to occur with various types. Retrievable filters should be retrieved in a timely manner, if possible, to avoid the long-term complications described.